Angela S. Guarda

Objective The COVID‐19 pandemic has been associated with increased hospitalization rates and worsened symptom severity in patients with eating disorders (ED), but most studies focused exclusively on adolescents. Further, research evaluating the impact of COVID‐19 on response to inpatient treatment for ED is limited. This study aimed to compare demographic characteristics, symptom severity at admission, and discharge outcomes for adult and adolescent inpatients with EDs admitted before and after onset of the COVID‐19 pandemic. We expected the post‐COVID cohort would report elevated symptomatology and poorer response to treatment compared to the pre‐COVID cohort and that this effect would be amplified for adolescents. Method Patients were consecutively hospitalized adults and adolescents treated in a specialized behavioral integrated inpatient‐partial hospitalization program for eating disorders between March 2018 and March 2022 ( N = 261). Results The effect of COVID‐19 on symptomatology was moderated by age group such that adolescents in the post‐COVID cohort, but not adults, reported higher levels of eating disorder and depressive symptoms compared to the pre‐COVID cohort. No group differences were observed for discharge outcomes (rate of weight gain, length of stay, or percent target weight). Discussion Findings with respect to elevated symptomatology in adolescents but not adults may reflect the particularly negative impact of social isolation on adolescents. Future research is needed to assess the impact of COVID‐19 on long‐term treatment outcomes including relapse at 1‐year, as well as the potential impact of COVID‐19 on treatment availability for chronically ill adults or those with public insurance. Public Significance Patients with eating disorders (ED) admitted to a specialty inpatient program after the start of the COVID‐19 pandemic were younger and more likely to be male than those admitted pre‐pandemic. Adolescents admitted post‐COVID, but not adults, reported elevated ED and depressive symptoms compared to the pre‐COVID cohort. Group differences were not observed for treatment response. Future research should evaluate the impact of COVID‐19 on relapse risk in EDs.